Trazodone
Active ingredient: Trazodone Hydrochloride
In short: Trazodone hydrochloride tablets are indicated for the treatment of major depressive disorder (MDD) in adults.
What is Trazodone used for?
Trazodone hydrochloride tablets are indicated for the treatment of major depressive disorder (MDD) in adults.
âš Boxed warning (FDA's strongest warning)
WARNING: SUICIDAL THOUGHTS and BEHAVIORS
Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors . Trazodone is not approved for use in pediatric patients .
Trazodone dosage
2.1 Dose Selection
An initial dose of 150 mg/day in divided doses is suggested. The dosage should be initiated at a low-dose and increased gradually, noting the clinical response and any evidence of intolerance. Occurrence of drowsiness may require the administration of a major portion of the daily dose at bedtime or a reduction of dosage.
The dose may be increased by 50 mg/day every 3 to 4 days. The maximum dose for outpatients usually should not exceed 400 mg/day in divided doses. Inpatients (i.e., more severely depressed patients) may be given up to but not in excess of 600 mg/day in divided doses.
Once an adequate response has been achieved, dosage may be gradually reduced, with subsequent adjustment depending on therapeutic response.
2.2 Important Administration Instructions
Trazodone hydrochloride tablets can be swallowed whole or administered as a half tablet by breaking the tablet along the score line.
Trazodone hydrochloride tablets should be taken shortly after a meal or light snack.
2.3 Screen for Bipolar Disorder Prior to Starting Trazodone
Prior to initiating treatment with trazodone hydrochloride tablets or another antidepressant, screen patients for a personal or family history of bipolar disorder, mania, or hypomania .
2.4 Switching to or from Monoamine Oxidase Inhibitor Antidepressant
At least 14 days must elapse between discontinuation of a monoamine oxidase inhibitor (MAOI) antidepressant and initiation of trazodone hydrochloride tablets. In addition, at least 14 days must elapse after stopping trazodone hydrochloride tablets before starting an MAOI antidepressant .
2.5 Dosage Recommendations for Concomitant Use with Strong CYP3A4 Inhibitors or Inducers
Coadministration with Strong CYP3A4 Inhibitors
Consider reducing trazodone dose based on tolerability when trazodone is coadministered with a strong CYP3A4 inhibitor .
Coadministration with Strong CYP3A4 Inducers
Consider increasing trazodone dose based on therapeutic response when trazodone is coadministered with a strong CYP3A4 inducer .
2.6 Discontinuation of Treatment with Trazodone
Adverse reactions may occur upon discontinuation of trazodone . Gradually reduce the dosage rather than stopping trazodone abruptly whenever possible.
Warnings & precautions
Do not take this medicine if: Trazodone hydrochloride tablets are contraindicated in:
Patients taking, or within 14 days of stopping, monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue, because of an increased risk of serotonin syndrome .
5.1 Suicidal Thoughts and Behaviors in Pediatric and Young Adult Patients
In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and over 4,400 pediatric patients, the incidence of suicidal thoughts and behaviors in pediatric and young adult patients was greater in antidepressant-treated patients than in placebo-treated patients. The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1,000 patients treated are provided in Table 1.
No suicides occurred in any of the pediatric studies. There were suicides in the adult studies, but the number was not sufficient to reach any conclusion about antidepressant drug effect on suicide.
Table 1 Risk Differences of the Number of Cases of Suicidal Thoughts or Behaviors in the Pooled Placebo-Controlled Trials of Antidepressants in Pediatric and Adult Patients
Age Range
(years)
Drug-Placebo Difference in Number of Patients of
Suicidal Thoughts or Behaviors per 1,000 Patients Treated
Increases Compared to Placebo
< 18
14 additional patients
18 to 24
5 additional patients
Decreases Compared to Placebo
25 to 64
1 fewer patient
≥ 65
6 fewer patients
It is unknown whether the risk of suicidal thoughts and behaviors in pediatric and young adult patients extends to longer-term use, i.e., beyond four months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with MDD that antidepressants delay the recurrence of depression. …
Trazodone side effects
The following serious adverse reactions are described elsewhere in the labeling:
Suicidal Thoughts and Behavior in Children, Adolescents and Young Adults
Serotonin Syndrome
Cardiac Arrythmias
Orthostatic Hypotension and Syncope
Increased Risk of Bleeding
Priapism
Activation of Mania or Hypomania
Discontinuation Syndrome
Potential for Cognitive and Motor Impairment
Angle-Closure Glaucoma
Hyponatremia
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Table 2 Common Adverse Reactions Occurring in ≥ 2% of Trazodone-treated Patients and Greater than the Rate of Placebo-Treated Patients as Observed in Controlled Clinical Studies
Inpatients
Outpatients
Trazodone
Placebo
Trazodone
Placebo
N=142
N=95
N=157
N=158
Allergic
Skin Condition/Edema
3%
1%
7%
1%
Autonomic
Blurred Vision
6%
4%
15%
4%
Constipation
7%
4%
8%
6%
Dry Mouth
15%
8%
34%
20%
Cardiovascular
Hypertension
20%
1%
1%
*
Hypotension
7%
1%
4%
0
Syncope
3%
2%
5%
1%
CNS
Confusion
5%
0
6%
8%
Decreased Concentration
3%
2%
1%
0
Disorientation
2%
0
*
0
Dizziness/Light-Headedness
20%
5%
28%
15%
Drowsiness
24%
6%
41%
20%
Fatigue
11%
4%
6%
3%
Headache
10%
5%
20%
16%
Nervousness
15%
11%
6%
8%
Gastrointestinal
Abdominal/Gastric …
Drug interactions
7.1 Drugs Having Clinically Important Interactions with Trazodone
Table 3 Clinically Important Drug Interactions with Trazodone
Monoamine Oxidase Inhibitors (MAOIs)
Clinical Impact
The concomitant use of MAOIs and serotonergic drugs including trazodone increases the risk of serotonin syndrome.
Intervention
Trazodone is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue [see Contraindications (4), Dosage and Administration (2.3, 2.4), and Warnings and Precautions (5.2)].
Examples
isocarboxazid, moclobemide, phenelzine, selegiline, tranylcypromine
Other Serotonergic Drugs
Clinical Impact
The concomitant use of serotonergic drugs including trazodone and other serotonergic drugs increases the risk of serotonin syndrome.
Intervention
Monitor patients for signs and symptoms of serotonin syndrome, particularly during trazodone initiation. If serotonin syndrome occurs, consider discontinuation of trazodone and/or concomitant serotonergic drugs .
Examples
triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort
Antiplatelet Agents and Anticoagulants
Clinical Impact
Serotonin release by platelets plays an important role in hemostasis. …
About this medicine
Trazodone hydrochloride is a selective serotonin reuptake inhibitor and 5HT2 receptor antagonist. Trazodone hydrochloride, USP is a triazolopyridine derivative designated as 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]- 1,2,4-triazolo[4, 3-a]pyridin-3(2H)-one hydrochloride. It is a white to off-white, crystalline powder which is sparingly soluble in chloroform and in water. The structural formula is represented as follows:
[Trazodone Hydrochloride Tablets USP]
Molecular Formula: C19H22ClN5O•HCl
Molecular Weight: 408.32
Each trazodone hydrochloride tablet, USP for oral administration contains 50 mg, 100 mg, 150 mg or 300 mg of trazodone hydrochloride, USP. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, pregelatinized starch, sodium lauryl sulfate, and sodium starch glycolate.
The Product meets USP Dissolution Test #2. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 5da5ee03-b0e2-fac7-e063-6294a90a121a. Read the full official label on DailyMed.
Related medicines
Sertraline Escitalopram Bupropion Fluoxetine Duloxetine Prednisone Buspirone Venlafaxine